Zenas BioPharma, Inc. Common Stock (ZBIO) is a publicly traded Healthcare sector company. As of November 5, 2026, ZBIO trades at $28.46 with a market cap of $1.85B and a P/E ratio of -2.22. ZBIO moved +0.00% today. Year to date, ZBIO is +71.02%; over the trailing twelve months it is -5.16%. Its 52-week range spans $6.11 to $44.60. Analyst consensus is strong buy with an average price target of $44.80. Rallies surfaces ZBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Zenas BioPharma Q3 2026 net loss more than doubles to $108.9 million: Zenas BioPharma’s third-quarter 2026 net loss more than doubled year over year to $108.9 million. Revenue was $10 million, and cash, cash equivalents and investments totaled $647.1 million at September 30.
| Metric | Value |
|---|---|
| Price | $28.46 |
| Market Cap | $1.85B |
| P/E Ratio | -2.22 |
| EPS | $-11.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.60 |
| 52-Week Low | $6.11 |
| Volume | 10 |
| Avg Volume | 0 |
| Revenue (TTM) | $5.00M |
| Net Income | $-156.99M |
| Gross Margin | 0.00% |
5 analysts cover ZBIO: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $44.80.